Moderna’s COVID-19 and Zika patent applications to be investigated

A US Department of Health and Human Services agency will investigate whether biopharmaceutical company, Moderna Therapeutics, fully disclosed information on government funding in patent applications relating to its COVID-19 vaccine candidate and its work on a Zika vaccine.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

WHO plans to vaccinate Africa with Moderna COVID vaccine hit stumbling block

16 September 2021 Just 12 African countries have hit WHO’s 10% vaccination target as supply chain issues worsen.

Big Pharma

Moderna won’t enforce COVID-19 patents

12 October 2020 Biopharmaceutical company, Moderna, has announced that it will not enforce patents related to its COVID-19 vaccine while the pandemic is ongoing, and that it is prepared to license the patents to others after the pandemic is over.

Americas

Moderna unsure of COVID-19 vaccine patent exclusivity

12 August 2020 US biotech company Moderna has said it’s possible that it may not be the first company to make the inventions claimed in its pending patent applications, which include the breakthroughs for its experimental COVID-19 vaccine.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Moderna’s COVID-19 and Zika patent applications to be investigated

More on this story

Editor's picks

Editor's picks

More features